X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal metabolic disorder caused by mutations in the ABCD1 gene, leading to accumulation of very long-chain fatty acids (VLCFAs, C22:0 to C26:0) in plasma and tissues including the brain, spinal cord, and adrenal cortex. It is one of the most common peroxisomal disorders, with an incidence of approximately 1 in 17,000 live births.
X-ALD affects multiple organ systems, particularly the nervous system and adrenal glands. The disease spectrum includes four main phenotypes:
| Phenotype |
Onset Age |
Prevalence |
Key Features |
| Childhood cerebral ALD (cALD) |
3-10 years |
~35% of males |
Rapid demyelination, cognitive decline, adrenal insufficiency |
| Adrenomyelopathy (AMN) |
20-40 years |
~40% of males |
Progressive spinal cord disease, bladder dysfunction, gait disturbance |
| Addison's disease |
Any age |
~50% of males |
Primary adrenal insufficiency, often precedes neurological symptoms |
| Adult cerebral ALD |
>18 years |
~5% of males |
Progressive demyelination, behavioral changes, dementia |
The ABCD1 gene on chromosome Xq28 encodes the peroxisomal ATP-binding cassette transporter D1 (ALDP), which is essential for importing very long-chain fatty acyl-CoA synthetase into peroxisomes for beta-oxidation. Loss of ALDP function blocks peroxisomal VLCFA metabolism.
The ABCD1 gene (ATP-binding cassette subfamily D member 1) spans approximately 20 kb on chromosome Xq28. It encodes a 745-amino-acid peroxisomal membrane protein belonging to the ATP-binding cassette (ABC) transporter family. ALDP forms homodimers that transport VLCFA-CoA synthetase from the cytosol into the peroxisomal matrix.
Over 900 pathogenic variants have been identified in ABCD1, distributed throughout the gene with no clear mutational hot spot:
- Missense mutations: ~60% of cases — affect protein folding, trafficking, or function
- Nonsense mutations: ~15% — premature stop codons, complete loss of function
- Frameshift mutations: ~15% — insertions/deletions causing truncations
- Splice site mutations: ~10% — abnormal mRNA processing
- Large deletions: Rare — complete or partial gene loss
A critical feature of X-ALD is the lack of clear genotype-phenotype correlation:
- Identical ABCD1 mutations can cause completely different phenotypes within the same family
- Male relatives with identical mutations may develop cALD, AMN, or no neurological disease
- This suggests significant modifier genes, epigenetic factors, and environmental influences
Several genes may modify X-ALD phenotype expression:
- ABCD2: Partial functional redundancy with ABCD1, may compensate when ABCD1 is deficient
- ABCD3: Also can transport VLCFA-CoA, may modify severity
- PEX genes: Peroxisome biogenesis genes that affect overall peroxisomal function
- APOE: May influence cerebral ALD progression
- X-linked recessive: Primarily affects males
- Female carriers: May develop mild AMN-like symptoms due to skewed X-inactivation (~20-50%)
- Almost all cases are de novo or inherited from carrier mothers
- No correlation between mutation type and severity
ABCD1 protein deficiency leads to X-ALD through several interconnected mechanisms:
- VLCFA accumulation: Impaired peroxisomal beta-oxidation causes VLCFAs to accumulate in plasma, fibroblasts, and all tissues
- Membrane dysfunction: Incorporation of VLCFAs into myelin membranes destabilizes the myelin sheath, predisposing to demyelination
- Mitochondrial dysfunction: VLCFAs induce mitochondrial dysfunction and increased oxidative stress
- Inflammatory response: Demyelination triggers astrocyte activation and pro-inflammatory cytokine release
- Adrenal cortex damage: VLCFAs are toxic to adrenal gland cells, causing adrenal insufficiency
- Rapid neurological decline: Cognitive regression, behavioral changes, motor dysfunction
- Visual/hearing impairment: Demyelination of visual and auditory pathways
- Adrenal insufficiency: Often precedes or accompanies neurological symptoms
- Prognosis: Without treatment, most die within 3-5 years of symptom onset
- Slowly progressive spinal cord disease: Spastic paraparesis, gait disturbance
- Bladder/bowel dysfunction: Urinary urgency, incontinence
- Peripheral neuropathy: Sensory and motor involvement
- Adrenal insufficiency: May develop or be present
- Progression: Typically over decades, may transition to cerebral ALD (10-20% risk)
- Mild neurological symptoms: Typically onset after age 50
- Myelopathy: Similar to AMN but milder
- Peripheral neuropathy: Common
- Variable expression: Only ~20% develop significant symptoms
- Plasma VLCFA analysis: Elevated C26:0, C24:0/C22:0 ratio, C26:0/LPC (key diagnostic marker)
- Performic acid oxidation coupled with GC-MS: More sensitive than standard VLCFA measurement
- Lorenzo's oil loading test: Fibroblast VLCFA accumulation assay
- ABCD1 sequencing: Confirms diagnosis and identifies specific variant
- Deletion/duplication analysis: For cases with no point mutation identified
- Newborn screening: Implemented in many US states and countries using C26:0-lyso-PC from dried blood spots
- MRI brain: Detects cerebral demyelination in cALD (confluent white matter changes, contrast enhancement at advancing edge)
- MRI spine: Shows spinal cord atrophy in AMN
- Hematopoietic stem cell transplantation (HSCT): For early cALD — can halt progression if performed before extensive demyelination
- Gene therapy (Skysona/Lenti-D): Autologous HSCT with lentiviral ABCD1 gene correction — FDA-approved for cALD in children not eligible for HSCT
- HSCT from unrelated donors: Alternative when no matched sibling donor
- Adrenal steroid replacement: Essential for all males with adrenal insufficiency
- Physical therapy: Maintain mobility, manage spasticity
- Urological management: Bladder management programs
- Nutritional support: For those with swallowing difficulties
- Psychosocial support: For patient and family
- Lorenzo's oil (glyceryl trioleate-trierucate): Mixed evidence for slowing progression
- Dietary VLCFA restriction: Limited efficacy
- PPAR-alpha agonists (fibrates): Investigational — upregulate alternative VLCFA metabolism
- STAT5B agonists: Under investigation